Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af Patritumab Deruxtecan med andre anticancermidler hos deltagere med HER2 positiv brystkræft, der har spredt sig og ikke kan fjernes kirurgisk (MK-1022-009)

12. november 2026 opdateret af: Merck Sharp & Dohme LLC

HERTHENA-Breast-01: Et fase 1b/2, multicenter, åbent, dosisfindende studie til evaluering af sikkerheden og antitumoraktiviteten af ​​Patritumab Deruxtecan hos deltagere med HER2-positiv ikke-operabel lokalt avanceret brystkræft eller metastatisk brystkræft

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

181

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Rekruttering
        • Kingston General Hospital ( Site 0061)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 6135336541
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Cancer Centre ( Site 0001)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 416-946-4501
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Rekruttering
        • Jewish General Hospital ( Site 0003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 514-340-8222
      • Montreal, Quebec, Canada, H2X 3E4
        • Rekruttering
        • Centre Hospitalier de l'Université de Montréal ( Site 0004)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: (514)890-8000 x20737
    • Camden
      • London, Camden, Det Forenede Kongerige, NW1 2PG
        • Rekruttering
        • University College London Hospital ( Site 0041)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +442034472930
    • Glasgow City
      • Glasgow, Glasgow City, Det Forenede Kongerige, G12 0YN
        • Rekruttering
        • The Beatson West of Scotland Cancer Centre ( Site 0043)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +441413017000
    • London, City of
      • London, London, City of, Det Forenede Kongerige, EC1A 7BE
        • Rekruttering
        • St Bartholomew s Hospital ( Site 0040)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +442073777000
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado Anschutz Medical Campus ( Site 0057)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 720-848-1030
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Dana-Farber Cancer Institute ( Site 0050)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 877-338-7425
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey ( Site 0052)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 732-235-2465
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 864-455-3600
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • Inova Schar Cancer Institute ( Site 0051)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 571-472-4724
      • Haifa, Israel, 3109601
        • Rekruttering
        • Rambam Health Care Campus ( Site 0011)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 04-7776234
      • Petah Tikva, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center ( Site 0012)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +972-505533121
      • Ramat Gan, Israel, 5265601
        • Rekruttering
        • Sheba Medical Center ( Site 0010)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 03-5304498
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 467-8602
        • Rekruttering
        • Nagoya City University Hospital ( Site 0020)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +81-52-851-5511
      • Seoul, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital ( Site 0030)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 82-2-2072-0850
      • Seoul, Sydkorea, 05505
        • Rekruttering
        • Asan Medical Center ( Site 0031)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82-2-1688-7575

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current leptomeningeal disease
  • Has clinically significant corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or brain metastases
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active HBV and HCV infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1: Patritumab deruxtecan plus trastuzumab

Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andre navne:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andre navne:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andre navne:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®
Eksperimentel: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andre navne:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andre navne:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andre navne:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Eksperimentel: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andre navne:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andre navne:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andre navne:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Tucatinib administered as oral tablets

Eksperimentel: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andre navne:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andre navne:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andre navne:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Tidsramme: Up to 21 days

DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Tidsramme: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Tidsramme: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Tidsramme: Up to approximately 36 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

Up to approximately 36 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Tidsramme: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 2: Duration of Response (DOR)
Tidsramme: Up to approximately 36 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Progression Free Survival (PFS)
Tidsramme: Up to approximately 36 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Number of Participants with One or More AEs
Tidsramme: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Tidsramme: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Medical Director, Merck Sharp & Dohme LLC

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. februar 2025

Primær færdiggørelse (Anslået)

2. august 2032

Studieafslutning (Anslået)

2. august 2032

Datoer for studieregistrering

Først indsendt

11. november 2024

Først indsendt, der opfyldte QC-kriterier

11. november 2024

Først opslået (Faktiske)

13. november 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1022-009
  • MK-1022-009 (Anden identifikator: MSD)
  • jRCT2041250022 (Registry Identifier: Japan Registry of Clinical Trials (jRCT))
  • 2026-528266-19 (Registry Identifier: EU CT)
  • U1111-1346-4321 (Registry Identifier: UTN)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .